ArticleJournal of cancer research and clinical oncology2026
Genetic analysis of genes GSTP1, PTEN, and TP53 SNPs in non-melanoma skin cancer patients.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveOne of the most prevalent cancers in the world, non-melanoma skin cancer (NMSC) is impacted by several genetic, demographic, and environmental factors. METHODOLOGY: This case-control study examined the relationship between NMSC susceptibility and GSTP1 (rs1695), PTEN (rs701848), and TP53 (rs17878362) polymorphisms in 300 Pakistani patients and 300 healthy controls. Additionally assessed were demographic factors such as age, gender, smoking status, and family history.
resultsThe findings showed a strong correlation between the risk of NMSC and all three SNPs. The heterozygous mutant genotype (AG) of GSTP1 rs1695 was significantly (p = 0.0053) associated with a higher risk of NMSC with a family history, while its heterozygote genotype (AG) was associated with smoking (p = 0.0001). The AG genotype was associated with an increased risk of disease in males and GG showed a significant (p = 0.0010) protective association in females. The heterozygous mutant (AG) genotype in the < 43 age while the homozygous mutant (GG) showed a lower disease risk (p = 0.0029) in the > 43 age group. Patients had a higher frequency of the heterozygous AG genotype (166, 55%) than controls (87, 29%) and homozygous mutant GG genotype (17, 6%) than controls (58, 19%), indicating a significant protective effect (OR = 0.25, 95% CI: 0.1-0.4; p = 0.0001).
conclusionThese correlations held true for age, gender, smoking status, and family history subgroups. The results indicate that these polymorphisms may function as potential genetic biomarkers for early detection and risk prediction, highlighting the crucial role of detoxification, tumor-suppressor, and DNA repair pathways in NMSC development. To confirm these findings, more extensive and useful research is advised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.